<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611346</url>
  </required_header>
  <id_info>
    <org_study_id>2022/CHU/15</org_study_id>
    <nct_id>NCT05611346</nct_id>
  </id_info>
  <brief_title>HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers</brief_title>
  <acronym>HypnoDA</acronym>
  <official_title>HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers : Study Protocol of a Pilot Randomized and Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis (AD) is a chronic inflammatory dermatosis, common in children. It causes&#xD;
      pruritus and skin lesions that can have a significant impact on patients' quality of life. AD&#xD;
      can be difficult to treat because of its chronicity, demanding local care, corticophobia and&#xD;
      the financial cost of non-reimbursed products. Patients are often looking for therapeutic&#xD;
      alternatives. Medical hypnosis is a therapeutic alternative via hypnoanalgesia induced by&#xD;
      direct suggestions of comfort and skin soothing and via anxiolysis, by working on stress&#xD;
      management and self-esteem reinforcement. Four studies are interested in its action in AD and&#xD;
      seem to show a reduction in pruritus, skin pain, an improvement in the intensity of atopic&#xD;
      dermatitis, sleep, mood and for some a cure of AD. These results are encouraging but limited&#xD;
      by the absence of a control group or by the small population included. Therefore, we propose&#xD;
      in a first step to evaluate the feasibility of an hypnosis program through a pilot study,&#xD;
      designed in the miniature format of a future, larger scale, randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Recruitment</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the patient recruitment rate in a pilot, randomized controlled study proposing a hypnosis program to children with moderate to severe AD.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Dermatitis</condition>
  <arm_group>
    <arm_group_label>Therapeutic education program</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic education program and Hypnosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hypnosis</intervention_name>
    <description>The experimental group will receive 2 standardized hypnosis sessions via the &quot;superhero costume&quot; technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording</description>
    <arm_group_label>Therapeutic education program and Hypnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 8 to 17 years&#xD;
&#xD;
          -  Understanding french&#xD;
&#xD;
          -  With moderate to severe AD clinically diagnosed by a physician (SCORing Atopic&#xD;
             Dermatitis (SCORAD) ≥ 25)&#xD;
&#xD;
          -  Referred by their referring physician in the Reunionese therapeutic education program&#xD;
             for AD provided within the atopy school of the Reunion University Hospital. - Oral&#xD;
             consent of the child and of one of the legal representatives collected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children refusing to participate in the hypnosis session&#xD;
&#xD;
          -  Not having the possibility to listen to an audio file,&#xD;
&#xD;
          -  Already practicing self-hypnosis for their AD before inclusion,&#xD;
&#xD;
          -  Having a contraindication to hypnosis (psychiatric disorders, psychosis)&#xD;
&#xD;
          -  Treated by a systemic treatment for their AD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliette MIQUEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de la Réunion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliette MIQUEL, MD</last_name>
    <phone>+262 262 35 90 00</phone>
    <email>juliette.miquel@chu-reunion.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille ESPAGNON, MD</last_name>
    <email>camille.espagnon@laposte.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Juliette MIQUEL, MD</last_name>
      <email>juliette.miquel@chu-reunion.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille ESPAGNON, MD</last_name>
      <email>camille.espagnon@laposte.net</email>
    </contact_backup>
    <investigator>
      <last_name>Juliette MIQUEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille ESPAGNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Réunion</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>January 6, 2023</last_update_submitted>
  <last_update_submitted_qc>January 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

